Medicine and Health
Neoadjuvant nivolumab with or without relatlimab in resectable non-small-cell lung cancer: a randomized phase 2 trial
M. Schuler, K. Cuppens, et al.
This study by Martin Schuler and colleagues reveals groundbreaking insights into preoperative nivolumab with or without relatlimab for non-small-cell lung cancer. With a remarkable 95% achieving curative resection and superior disease-free survival rates in the combination group, this research highlights the potential of immunotherapy in reshaping lung cancer treatment.
Playback language: English
Related Publications
Explore these studies to deepen your understanding of the subject.
